<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902653</url>
  </required_header>
  <id_info>
    <org_study_id>DV-MV-MO</org_study_id>
    <nct_id>NCT02902653</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Hourly Titrated Misoprostol Versus Vaginal Dinoprostone and Misoprostol for Cervical Ripening and Labor Induction</brief_title>
  <official_title>Efficacy and Safety of Hourly Titrated Misoprostol Versus Vaginal Dinoprostone and Misoprostol for Cervical Ripening and Labor Induction: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oihane Lapuente Ocamica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of the administration of oral misoprostol versus
      vaginal dinoprostone and vaginal misoprostol for cervical ripening and labor induction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the percentage of women in each group who achieved vaginal delivery within 24 hours after the beginning of administration in each group (oral misoprostol, vaginal misoprostol and intravaginal dinoprostone)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of women who manage cervical favorable conditions at 12 hours after the beginning of administration in each group</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of women who manage cervical favorable conditions at 24 hours after the beginning of administration in each group</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of women in each group who achieved vaginal delivery at 12 hours after the beginning of administration in each group</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the number of women who achieve a vaginal delivery in the 3 groups (oral misoprostol, vaginal misoprostol and intravaginal dinoprostone)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of caesarean sections in each group (oral misoprostol, vaginal misoprostol and intravaginal dinoprostone)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the percentage of women requiring oxytocin in each group</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of women in each group having tachysystole</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the number of women suffering from uterine rupture in each group</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of women in each branch having uterine hypertonia</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbility-mortality among pregnant participants</measure>
    <time_frame>up to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare fetal or neonatal morbility-mortality among the 3 groups</measure>
    <time_frame>up to 180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Labor, Induced</condition>
  <arm_group>
    <arm_group_label>Oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of oral misoprostol according to a &quot;3x1&quot; diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal misoprostol, 25 microgs every 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal dinoprostone, 10 mg during 24 hours (maximum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral misoprostol</intervention_name>
    <description>hourly titrated misoprostol</description>
    <arm_group_label>Oral misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal misoprostol</intervention_name>
    <description>Administration of 25 microgs every 6 hours, maximum 150 microgr</description>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal dinoprostone</intervention_name>
    <description>Vaginal delivery system of 10mg of dinoprostone</description>
    <arm_group_label>Vaginal dinoprostone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over 18

          -  single pregnancy

          -  cephalic presentation

          -  intact membranes

          -  unfavorable cervix ( less than 6 Bishop )

          -  CTGR not reactive decelerative

          -  Signed informed consent by the patient.

        Exclusion Criteria:

          -  prior Cesarean section or previous uterine surgery .

          -  Allergy or intolerance to any of the study drugs

          -  stillbirth

          -  uterine growth restricted fetuses

          -  contraindication for vaginal delivery

          -  Anterior placenta

          -  Multiparity

          -  moderate to severe heart disease

          -  hypertensive disorders of pregnancy

          -  Suspected chorioamnionitis

          -  Coagulation disorders

          -  history of epileptic seizures

          -  liver or kidney disease

          -  Cognitive impairment or bad knowledge of Spanish
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oihane Lapuente Ocamica</last_name>
    <role>Principal Investigator</role>
    <affiliation>OIHANE.LAPUENTEOCAMICA@osakidetza.eus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oihane Lapuente Ocamica</last_name>
    <email>OIHANE.LAPUENTEOCAMICA@osakidetza.eus</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Lopez Picado</last_name>
    <email>amanda.lopezpicado@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Araba University Hospital</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <state>Basque Country</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oihane Lapuente Ocamica</last_name>
      <email>OIHANE.LAPUENTEOCAMICA@osakidetza.eus</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Lopez Picado</last_name>
      <email>amanda.lopezpicado@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Basque Health Service</investigator_affiliation>
    <investigator_full_name>Oihane Lapuente Ocamica</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>dinoprostonal</keyword>
  <keyword>induction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

